In addition, we found that three cohorts of bladder cancer, glioblastoma, and melanoma with low LUM expressions had higher survival outcomes after ICB treatment, confirming the importance of low LUM levels in immunotherapy. The gene discussed is LUM; the disease is glioblastoma.